Table 3 Magnetic resonance spectroscopy changes after bumetanide administration.

From: Symptom improvement in children with autism spectrum disorder following bumetanide administration is associated with decreased GABA/glutamate ratios

MRS measures

Control

Bumetanide

Group comparisons

n

Mean

SD

n

Mean

SD

F

f.p

f.df

perm.p

fdr.p

Group (before treatment)

INS.GABA/NAA

14

0.39

0.05

38

0.43

0.07

5.27

0.0262

47

0.0260

 

INS.GABA/Glx

14

0.35

0.05

38

0.39

0.07

4.80

0.0335

47

0.0463

 

VC.GABA/NAA

17

0.38

0.06

36

0.40

0.05

2.73

0.1049

48

0.1550

 

VC.GABA/Glx

17

0.40

0.06

36

0.46

0.06

11.01

0.0017

48

0.0013

 

Group (after treatment)

INS.GABA/NAA

10

0.41

0.08

36

0.39

0.05

1.20

0.2801

41

1.0000

 

INS.GABA/Glx

10

0.35

0.06

36

0.34

0.04

0.83

0.3673

41

0.9983

 

VC.GABA/NAA

15

0.36

0.05

38

0.37

0.05

0.04

0.8502

48

0.9280

 

VC.GABA/Glx

15

0.42

0.05

38

0.42

0.05

0.06

0.8037

48

0.9427

 

Time × Group (change between before and after treatment)

INS.GABA/NAA

      

5.06

0.0299

41

0.0313

0.0418

INS.GABA/Glx

      

6.16

0.0173

41

0.0147

0.0418

VC.GABA/NAA

      

1.41

0.2406

48

0.2279

0.2279

VC.GABA/Glx

      

5.47

0.0236

48

0.0293

0.0418

  1. perm.p p value given by 3000 random permutations, fdr.p false discovery rate corrected p value
Back to article page